GC-AESTHETICS
GC Aesthetics® (GCA), a privately-held medical technology company providing aesthetic and reconstruction solutions for global healthcare markets, is proud to announce that its breast implant, PERLE™, has been featured in a recent independent peer-reviewed article published in the Aesthetic Surgery Journal Open Forum. The study, led by Mr. Taimur Shoaib (UK) highlights the safety and performance of PERLE, the round smooth opaque breast implant with the unique Bio-Q™ surface and 6th generation gel.
This is the first-time clinical data on PERLE is published in an international journal, proving safety and performance of this breast implant.
A cohort of 374 patients was retrospectively analyzed, with an average follow-up duration of 18 months. The study highlights low complications rates when using PERLE™ implants.
“I performed this study to examine the safety of PERLE implants. We introduced these implants into my clinic, La Belle Forme in Glasgow, at the beginning of 2021 when I heard about the science behind them. Every empirical aspect of the implant fitted in with my idea of high quality and I wanted to test this. We followed up 374 patients, with PERLE implants, over an average of 18 months. Our study showed that the safety profile of these implants is comparable with other modern implants with no implant related complications and no cases of capsular contracture,” mentioned Mr. Taimur Shoaib.
This independent clinical study validates the quality and safety of PERLE breast implants, meeting the standards and expectations of both surgeons and patients.
Chris Brotherston, Head of Quality, Regulatory and Clinical Affairs for GC Aesthetics, commented, "This is not just a milestone for GC Aesthetics; it's a validation of our commitment to safety and delivering outstanding results. We are also proud to announce the initiation of our 10-year prospective study on PERLE in Q1 of 2024, to continue collecting critical data and to extend its safety and enhanced compatibility profile.”
Read the full article here: Zhi Yang Ng, Calum Honeyman, Taimur Shoaib, Single-Institution Early Experience With a New, Smooth, Opaque, and Round Breast Implant Over a 2-Year Period, Aesthetic Surgery Journal Open Forum, Volume 5, 2023, ojad090, https://doi.org/10.1093/asjof/ojad090
About GC Aesthetics®
GC Aesthetics® is a long-established global medical technology company that develops, manufactures, and markets a comprehensive range of proprietary aesthetic and reconstructive products.
Throughout its 40-year history, GCA® has been dedicated to advancing the science of medical aesthetics and delivering high-quality breast implants for breast augmentation and breast reconstructive surgery. We have sold more than 3 million implants across 70 countries, and our products are supported by published 10-year clinical data.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240119352646/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KRAFTON Achieves Record-High Quarterly Sales in Q1 202529.4.2025 09:00:00 CEST | Press release
Thanks to PUBG IP expansion, inZOI’s strong debut, and BGMI’s global growth, quarter-over-quarter sales are up 41.6%, while operating profit is up 112.2% KRAFTON, Inc. today announced its first quarter earnings results for 2025. Based on consolidated financial statements prepared in accordance with Korean International Financial Reporting Standards (K-IFRS), the company achieved a record-high quarterly sales performance of 874.2B KRW and operating profit of 457.3B KRW. In addition to high quarter-over-quarter growth, year-over-year growth has also set records with sales up by 31.3% and operating profit upby 47.3%. Significant Growth and Core IP Direction KRAFTON achieved significant growth across all of its business divisions, including PC (323.5B KRW), mobile (532.4B KRW), and console/others (18.3B KRW). On PC platforms, PUBG: BATTLEGROUNDS’ diversified content and strong live-service operations contributed significantly to growth while the successful launch of a new IP, inZOI, also p
Azalea Vision Raises €9 Million in First Closing of Series A to Further Develop Intelligent Connected Vision Platform29.4.2025 09:00:00 CEST | Press release
Industry veteran Robert J. Dempsey Appointed Chairman of the Board to Guide Strategic Growth in Europe and the U.S. Azalea (A-zuh-lay-ah)Vision, a HealthTech company engineering the future of sight, today announced the first closing of its €15 million Series A funding round, raising €9 million along with the appointment of Robert J. Dempsey as Chairman of the Board to guide strategic growth in the European and U.S. markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429247873/en/ Robert Dempsey, Chairman of the Board, Azalea Vision "Strong participation from repeat investors in this Series A milestone reaffirms their trust in our medical device and innovation for the future of intelligent ocular health,” said Enrique Vega, CEO of Azalea Vision. “Additional funding in this round from SPRIM Global Investments and Afrimobility, along with a strategic investor who remains undisclosed, further emphasizes the confidence in
A Third of Global CIOs Warn of Unrealistic Board Expectations as The World Bets Big on AI, According to Expereo29.4.2025 09:00:00 CEST | Press release
A new survey commissioned by Expereo exposes the true roadblocks to global AI plans - poor infrastructure, resistance from employees, unreasonable demands A third of global technology leaders believe their board has unrealistic expectations or demands on how new technologies like AI will impact business performance. This is according to an IDC InfoBrief*, commissioned by Expereo, which highlights serious roadblocks to global AI implementation, despite AI being considered critical to fulfilling business priorities. The research of 650 technology leaders in global organizations across Europe, the US and APAC reveals that 34% of global technology leaders have been forced to reassess their technology infrastructure because of rising geopolitical risks, as 37% say geopolitical disruptions are currently impacting their organization’s growth strategies. Amid the volatile economic backdrop, it seems most organizations are placing their bets on AI to drive growth. The research shows that 87% of
Cyber Guru Named Winner of the Coveted Global InfoSec Awards during RSA Conference 202529.4.2025 09:00:00 CEST | Press release
Cyber Guru Wins Hot Company in Security Awareness Training in the 13th Annual Global InfoSec Awards at #RSAC 2025 Cyber Guru, the leading cybersecurity awareness training platform, is proud to announce we have won the “Hot Company - Security Awareness Training” award from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250429950821/en/ Cyber Guru, Global InfoSec Award Winner 2025 “We’re thrilled to receive one of the most prestigious and coveted cybersecurity awards in the world from Cyber Defense Magazine, during their 13th anniversary as one of the world’s leading independent cybersecurity news and information provider. We knew the competition would be tough and with top judges who are leading infosec experts from around the globe, we couldn’t be more pleased,” said Gianni Baroni, CEO and founder of Cyber Guru. Cyber Guru embodies
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner29.4.2025 07:52:00 CEST | Press release
Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes. Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom